Gene Therapy Offers Hope for Rare Pitt Hopkins Syndrome
Berlin, Germany – In a significant step forward for patients with Pitt Hopkins syndrome, Mahzi Therapeutics has administered the first dose of its investigational gene therapy, MZ-1866, in a Phase I/II clinical trial dubbed UNITE. This milestone, reached on February 26, 2026, offers a beacon of hope for individuals and families affected by this rare and debilitating genetic disorder. The trial, a multi-center, open-label study, will assess the safety, tolerability, and potential efficacy of a single administration of MZ-1866. Pitt Hopkins syndrome, a condition impacting roughly one in 34,000 to 41,000 people, presents a complex array of challenges, and currently has limited treatment options.
The UNITE study is designed to enroll approximately 12 participants across five clinical sites located in the United States, Spain, and Israel. Participants, all with genetically confirmed Pitt Hopkins syndrome, will receive a single dose of MZ-1866 delivered directly into the brain via intracerebroventricular administration. Researchers will meticulously monitor participants for safety, while also evaluating changes in cognitive function, communication skills, developmental progress, and motor abilities. These exploratory endpoints aim to provide early indications of the therapy’s potential impact on the core symptoms of the syndrome.
Understanding Pitt Hopkins Syndrome and the Role of TCF4
Pitt Hopkins syndrome is a genetic disorder caused by mutations in the TCF4 gene. This gene provides instructions for making a protein crucial for brain development. Mutations in TCF4 disrupt this process, leading to a range of neurodevelopmental challenges. Symptoms often manifest in early childhood and can include intellectual disability, delayed speech development, autistic-like behaviors, breathing irregularities like apnea and hyperventilation, low muscle tone (hypotonia), and gastrointestinal issues. While the severity of symptoms varies, the condition significantly impacts quality of life for both individuals and their families. Approximately 8,000 people in the United States are currently living with Pitt Hopkins syndrome, according to estimates from Mahzi Therapeutics.
How MZ-1866 Works: A Gene Therapy Approach
MZ-1866 represents a novel approach to treating Pitt Hopkins syndrome by directly addressing the underlying genetic cause. The therapy utilizes an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the TCF4 gene to brain cells. Specifically, MZ-1866 incorporates TCF4 isoform B, the longest and most abundant isoform of the TCF4 protein found in the brain, into an AAV9 expression cassette. This cassette is regulated by multimer E box sequences, designed to ensure targeted gene expression. The AAV9 vector is chosen for its ability to efficiently cross the blood-brain barrier, a significant hurdle in delivering therapies to the central nervous system. This gene replacement strategy aims to restore the production of functional TCF4 protein, potentially mitigating the neurological deficits associated with the syndrome.
Collaboration and Funding Behind the Breakthrough
The development of MZ-1866 is a collaborative effort between Mahzi Therapeutics and the Muotri Lab at the University of California, San Diego. Dr. Alysson Muotri’s lab has been instrumental in understanding the role of TCF4 in brain development and in designing the gene therapy approach. Mahzi Therapeutics details this collaboration on their pipeline page. The Phase I/II UNITE study is also supported by funding from the California Institute for Regenerative Medicine (CIRM), highlighting the importance of public investment in innovative therapies for rare diseases. The CIRM’s commitment to regenerative medicine research has been crucial in advancing this promising treatment towards clinical evaluation.
What are AAV9 Vectors and Why are They Important?
Adeno-associated viruses (AAVs) are tiny viruses that are not known to cause disease in humans. Scientists have harnessed their ability to deliver genetic material into cells, making them ideal vectors for gene therapy. AAV9, in particular, has shown promise in crossing the blood-brain barrier, making it a preferred choice for treating neurological disorders. The AAV9 vector in MZ-1866 acts as a delivery vehicle, carrying the functional TCF4 gene into brain cells without triggering an immune response. This targeted delivery is critical for maximizing therapeutic benefit and minimizing potential side effects.
Looking Ahead: Next Steps in the UNITE Trial
The dosing of the first patient marks a critical milestone, but the UNITE trial is just beginning. Researchers will now closely monitor the patient for any adverse events and assess the initial impact of MZ-1866. As more participants are enrolled and treated, the study will gather valuable data on the safety and efficacy of the therapy. The primary objective of the Phase I/II trial is to evaluate safety, but the exploratory endpoints will provide early signals of potential clinical benefit. Mahzi Therapeutics CEO Yael Weiss expressed optimism about the program’s potential, stating, “Dosing the first patient is a significant achievement…We look forward to advancing this program to address a significant unmet medical need.”
The next key milestone for the UNITE trial will be the completion of patient enrollment and the collection of initial safety and efficacy data. Mahzi Therapeutics anticipates sharing preliminary results from the trial in late 2027 or early 2028. These findings will be crucial in determining the future development of MZ-1866 and its potential to transform the lives of individuals with Pitt Hopkins syndrome. Families and advocates are eagerly awaiting updates from the trial, hoping that this innovative gene therapy will offer a lasting solution to this challenging condition.
Key Takeaways:
- Mahzi Therapeutics has dosed the first patient in a Phase I/II trial of MZ-1866, a gene therapy for Pitt Hopkins syndrome.
- MZ-1866 aims to deliver a functional copy of the TCF4 gene to brain cells using an AAV9 vector.
- The UNITE trial will assess the safety, tolerability, and potential efficacy of MZ-1866 in approximately 12 participants.
- The development of MZ-1866 is a collaborative effort between Mahzi Therapeutics and the Muotri Lab at UC San Diego, with funding from the California Institute for Regenerative Medicine.
The progress of the UNITE trial will be closely watched by the medical community and the Pitt Hopkins syndrome community alike. For more information about Pitt Hopkins syndrome and ongoing research efforts, please visit the Pitt Hopkins Syndrome Foundation website. We encourage readers to share this article and engage in the conversation about this promising recent therapy.